Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1005 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Transcept Pharma refiles Intermezzo NDA

Intermezzo is indicated for the treatment of insomnia or sleeping disorders. The refiling of the application follows a meeting between Transcept and the FDA, to discuss the issues